CellBiotech's drug for atopic therapy to complete clinical studies.

Published: 2005-09-20 06:56:00

Updated: 2005-09-20 06:56:00

CellBiotech announced on Sept. 14 that a domestic clinical study on the new drug developed from a lactobacillus bacteria, a combined ATP lactobacillus, for the treatment of atopic skin diseases was successfully completed.

The study for its efficacy and safety via oral administration of the ATP...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK